---
title: "Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial"
id: "clinicaltrials-nct06980025"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct06980025"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT06980025"
doi: "NCT06980025"
published_at: "2026-04-09T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct06980025
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT06980025)
- **DOI:** [NCT06980025](https://doi.org/NCT06980025)
- **Published At:** 2026-04-09T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
RECRUITING · INTERVENTIONAL · PREVENTION study · Preterm Delivery · Phase 3 · Enrollment 1800 · Sponsor: The George Washington University Biostatistics Center
## Clinical Analysis & Structured Key Points
Official title: A Dose Escalation Study of Low Dose Aspirin for the Prevention of Recurrent Preterm Birth Summary: This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation. Conditions: Preterm Delivery, Obstetrical Complications Keywords: Preterm Delivery, Stillbirth, Maternal Morbidity, Neonatal Morbidity, Prevention Study type: INTERVENTIONAL Primary purpose: PREVENTION Phases: PHASE3 Enrollment: 1800 (ESTIMATED) Status: RECRUITING Completion: 2029-02-28 (ESTIMATED)
## Related Clinical Research

- [Aspirin and Vaginal Inflammation: In Vivo Effects (Article Content Not Available)](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-evaluating-the-in-vivo-effects-of-aspirin-on-vaginal-inflammation-and-barrier.md)
- [Heparin-induced thrombocytopenia during therapeutic plasma exchange in neuromyelitis optica: singl](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-confirmed-and-suspected-heparin-induced-thrombocytopenia-during.md)
- [Pulmonary artery growth after PDA stent versus modified Blalock–Taussig shunt in ductal-dependent](https://medichelpline.com/clinical-feed/plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent.md)
- [Cost-effectiveness of rivaroxaban plus aspirin in COMPASS: a Scandinavian lifetime analysis](https://medichelpline.com/clinical-feed/pubmed-42700109.md) (DOI: 10.1080/14017431.2026.2728343)
- [Three Common Drugs Older Adults May Be Overusing: Benzodiazepines, Antibiotics, Aspirin](https://medichelpline.com/clinical-feed/kff-health-news-2-3-common-drugs-older-adults-might-be-overusing.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.